🇺🇸 FDA
Pipeline program

DNTH103

DNTH103-MG-201

Phase 2 small_molecule active

Quick answer

DNTH103 for Myasthenia Gravis, Generalized is a Phase 2 program (small_molecule) at Dianthus Therapeutics, Inc. /DE/ with 1 ClinicalTrials.gov record(s).

Program details

Company
Dianthus Therapeutics, Inc. /DE/
Indication
Myasthenia Gravis, Generalized
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials